argenx SE Earnings Recaps
Q3 2026
Oct 25, 2026
Shares fell 1.8% after earnings, a roughly flat reaction. The quarter showed continued revenue growth, while management emphasized future launches and pipeline milestones rather than offering a new outlook in the provided transcript.
Key takeaways
- Product net sales were $1.7 billion, up 54% year over year and 13% quarter over quarter.
- U.S. product net sales were $1.5 billion, up 16% quarter over quarter; gross-to-net deductions were 22%, in line with company expectations.
- Management expects five potential launches in 2027, including pediatric and ocular MG opportunities, an auto-injector, and potential launches across other programs.
- Argenx expects to file an sBLA for VYVGART in IMNM by year-end and anticipates the EMPASSION Phase III readout in MMN in December.
- FB102 reported positive Phase II results in celiac disease and is ready to advance into Phase III.